
Shares in Tylenol-maker Kenvue tumbled after reports that US Health Secretary Robert F. Kennedy Jr. is preparing to unveil a controversial autism study.
The forthcoming research is expected to link prenatal Tylenol use and folate deficiencies to developmental disorders, triggering fierce debate, investor jitters and a storm of online speculation.